Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

5 Jan 2010 09:00

RNS Number : 0210F
ViaLogy PLC
05 January 2010
 

VIALOGY PLC ("VIALOGY" OR "THE COMPANY")

JANUARY BUSINESS UPDATE

Signs QuantumRD contract with one of US's largest independents

Multiple wells scheduled for Q1

Milestone achieved on University of Texas collaboration site

LondonJanuary 5, 2010ViaLogy (LSE:VIY) ViaLogy announces it is under contract to provide its QuantumRD hydrocarbon reservoir discovery and characterization services to one of the largest privately held Independent Exploration & Production companies in America. Headquartered in Oklahoma, the firm operates internationally and across the United States both onshore and offshore. It currently controls over 4,000 wells. The contract represents an important opportunity for ViaLogy to expand the scope of its QuantumRD technology into new formations. The initial collaboration is focused on discovery and characterization of Pennsylvanian Morrow Sandstone at the Mescalero Springs prospect in Chaves CountyNew Mexico. ViaLogy will analyze 3-D seismic data to discover oil and gas stratigraphic targets with porosity to position wells between 11,000 ft and 12,000 ft depths, and deliver its recommendations in four weeks. The project will further validate QuantumRD's ability to resolve stratigraphic prospects below seismic resolution presently achievable by conventional processing. At the client's request, neither the firm's name nor details of the signed contract will be made public. 

ViaLogy also announces the signing of a contract for QuantumRD with Nordan Oil & Gas Corporation of AbileneTexas, that foresees multiple QuantumRD analysis projects.

These and other new contracts bring ViaLogy's current client base to eight, and its contingent order book of wells to more than 50 (based on the approximate number of drill locations the company expects to provide to clients under signed contracts to date). The company also reports a strong sales pipeline of prospective clients which should extend the use of QuantumRD to an increasing variety of geographical locations and geophysical formations.

The first quarter of 2010 is scheduled to see multiple wells drilled at locations already determined by ViaLogy's QuantumRD analysis. Once the company's recommendations are made, the dates and pace of drilling are decided solely by ViaLogy's clients and depend upon the clients' operational priorities, and such matters as permits, equipment availability, and even weather. In this connection, Atascosa Exploration's planned Escondido well, initially expected at the end of last year, has been delayed until this month due to unexpected lease issues. During the first quarter of this year the two successful wells already identified for Atascosa by ViaLogy will undergo rework to accelerate their production. Their estimates of recoverable barrels of oil remain unchanged. 

ViaLogy's collaboration with another large Texas independent oil and gas exploration company in conjunction with the University of Texas' Bureau of Economic Geology, announced in a July 2009 press release, has concluded an important milestone. Despite previous expert analysis, the chosen site had produced a number of 'dry holes'. ViaLogy's application of QuantumRD to existing data sets has determined new drill location recommendations, and drilling on this challenging 11,000 ft well is slated for the coming weeks. 

ViaLogy's work for Vecta Oil & Gas, announced in September, 2009 and also with the involvement of the Bureau of Economic Geology, has concluded its first phase with the delivery of ViaLogy's QuantumRD analysis and recommended multiple drilling locations. A number of these wells are scheduled for drilling in 2010.

Commenting on the latest New Mexico contract, ViaLogy CEO Robert W. Dean, said, "We are pleased and proud to be working for a company of this firm's stature and experience. They are at the forefront of the industry in applying the most advanced analytical tools, and our hope is to become a mainstay of support in their drilling efforts." On the larger picture regarding QuantumRD, Dean goes on to say "ViaLogy now has a full workload and looks forward to significant business breakthroughs in the coming months, always bearing in mind that we cannot be successful 100 percent of the time."

ViaLogy

Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807)

Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 (mobile: 07860 842756) 

Nominated Advisor to ViaLogy PLC (Seymour Pierce)

Mark Percy +44 (0) 20-7107-8000

About ViaLogy: Network Centric Signal Processing

ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. ViaLogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.ViaLogy.com

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUGUMAGUPUURA
Date   Source Headline
7th Feb 20177:00 amRNSSouthern Europe Business Update
10th Jan 20173:33 pmRNSResult of General Meeting
10th Jan 20177:15 amRNSHardman Research: Yourgene improves growth
21st Dec 20164:00 pmRNSPosting of Circular
21st Dec 20167:00 amRNSHalf year results
21st Dec 20167:00 amRNSConditional Acquisition of Yourgene Bioscience
21st Nov 20167:00 amRNSPremaitha establishes first service lab in Asia
31st Oct 20167:00 amRNSPremaitha welcomes UK Govt. decision on NIPT
27th Oct 20164:10 pmRNSResult of AGM
27th Oct 20167:00 amRNSAGM Statement
21st Oct 20167:00 amRNSGrant of Options
3rd Oct 20167:15 amRNSHardman Research: Excellent first year for IONA®
30th Sep 20163:38 pmRNSNotice of AGM
30th Sep 20167:00 amRNSFinal Results
23rd Sep 201610:42 amRNSHolding(s) in Company
23rd Sep 20168:50 amRNSNotice of results & appointment of broker
23rd Sep 20168:50 amRNSInvestment agreement extension with Thermo Fisher
8th Sep 20169:08 amRNSDirectorate Change
6th Jul 20167:00 amRNSDirectorate Change
4th Jul 20167:00 amRNSProgress on anti-trust objections to litigation
22nd Jun 20167:00 amRNSAdoption of Financial Reporting Standard (FRS) 101
22nd Apr 201610:45 amRNSUpdate on competitor patent litigation
20th Apr 201611:14 amRNSHardman Research: IONA sales & litigation update
20th Apr 20167:00 amRNSPatent Litigation Rescheduled
18th Apr 20161:13 pmRNSHardman & Co Issues Research Report
18th Apr 20161:03 pmRNSHardman & Co Issues Research Report
14th Apr 20167:00 amRNSHolding(s) in Company
13th Apr 20169:52 amRNSHolding(s) in Company
13th Apr 20167:00 amRNSHoldings in Company, Director's Shareholding
11th Apr 20167:00 amRNSTrading Update
29th Mar 20167:00 amRNSPremaitha announces tenth customer laboratory
21st Mar 20167:00 amRNSDistribution Agreements in the Middle East
9th Mar 20165:21 pmRNSHolding in Company, Directors' Dealing Replacement
9th Mar 20163:33 pmRNSHolding in Company, Directors' Dealings
9th Mar 20167:00 amRNSDistribution Agreement with GeNext - Russia
7th Mar 20167:00 amRNSAppointment of Joint Broker
3rd Feb 20167:00 amRNSPremaitha partners with Visional Medical in India
2nd Feb 20167:00 amRNSPremaitha partners with Leeds Hospitals NHS Trust
28th Jan 20167:00 amRNSHardman & Co Research Report: IONA®-Up and running
27th Jan 20167:00 amRNSTwo new customers signed for clinical lab service
26th Jan 20162:29 pmRNSUpdate on UK Litigation Timing
15th Jan 20167:00 amRNSPremaitha welcomes NSC recommendation on NIPT
8th Jan 201612:40 pmRNSUpdate on competitor patent litigation
18th Dec 20157:00 amRNSDirector/PDMR Shareholding
16th Dec 20155:53 pmRNSHolding(s) in Company
15th Dec 20157:00 amRNSHardman Issues Research Report
14th Dec 20157:00 amRNSInvestment Agreement with Thermo Fisher Scientific
14th Dec 20157:00 amRNSHalf Yearly Report
11th Dec 20157:00 amRNSNotice of Half Year Results
2nd Dec 20157:00 amRNSFirst IONA® testing service in France at LaboSud

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.